A Phase 3, Multicenter, Randomized, Double-blind Trial of Brexpiprazole as Combination Therapy with Sertraline in the Treatment of Adults with Post-traumatic Stress Disorder
A Trial of Brexpiprazole and Sertraline in the Treatment of Post-Traumatic Stress Disorder
Sponsor: Otsuka Pharmaceuticals
Enrolling: Male and Female Patients
Study Length: 4 Months
Clinic Visits: 11
IRB Number: 7912
U.S. Govt. ID: NCT04124614
Contact: Gloria Gomez: (646) 450-4572 / gloria.gomez@nyspi.columbia.edu
Additional Study Information: We are currently enrolling individuals with post-traumatic stress disorder (PTSD) to participate in this research study. The purpose of this research study is to evaluate the effectiveness of an investigational medication, brexpiprazole, for PTSD. Eligible participants will be randomly assigned to receive either brexpiprazole, sertraline (also known as Zoloft), or a placebo (a pill without active study drug), or a combination of these. Additionally, participants will complete questionnaires and be monitored by a medical professional throughout the study. Some clinic visits will be conducted virtually via phone or video. Participants will be compensated for their time and be reimbursed for travel expenses to and from the clinic.
This study is closed
Franklin Schneier, MD
Do You Qualify?
Are you between the ages of 18-65? Yes No
Have you ever experienced or witnessed a stressful or life-threatening event (e.g., car accident, physical assault)? Yes No
Have you been bothered by this event for at least 6 months (e.g., nightmares, unwanted memories, avoiding people or places)? Yes No
You may be eligible for this study

Place Holder

For more information, please contact:
Gloria Gomez
(646) 450-4572